Clinical trials: Diabetic Peripheral Neuropathic Pain
Diabetic Neuropathy, Painful
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy.
- Trial name
- NCT01332149
- Testing
- Pregabalin
- Where
- 30 sites in China
- Volunteers
- 626 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain, Diabetic Neuropathy
A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving pain due to Diabetic Neuropathy.
- Trial name
- NCT00710424
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 297 people
- Sponsor
- Jazz Pharmaceuticals
Pain
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
- Trial name
- NCT00415597
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- Where
- 58 sites in United States
- Volunteers
- 467 people
- Sponsor
- Pfizer
Painful Diabetic Neuropathy, Diabetes
A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN.
- Trial name
- NCT02355158
- Testing
- clonidine hydrochloride topical gel, 0.1%
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- BioDelivery Sciences International
Diabetic Neuropathy, Painful
Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of the study is to learn if long-term treatment with DVS SR is safe for treating the pain and other symptoms associated with diabetic peripheral neuropathy.
- Trial name
- NCT01050218
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Volunteers
- 237 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetic Neuropathy, Painful
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to…
- Trial name
- NCT00385671
- Testing
- duloxetine hydrochloride, pregabalin, gabapentin
- Where
- 9 sites in United States, Germany
- Volunteers
- 407 people
- Sponsor
- Eli Lilly and Company
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic peripheral neuropathy.
- Trial name
- NCT02427464
- Testing
- Engensis (VM202)
- Where
- 25 sites in United States
- Volunteers
- 507 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Peripheral Neuropathic Pain
DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain
Investigate the efficacy and safety of DS-5565 in subjects with Diabetic Peripheral Neuropathic Pain (DPNP) in comparison to placebo
- Trial name
- NCT02318706
- Testing
- DS-5565
- Where
- Japan
- Volunteers
- 854 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Painful Diabetic Neuropathy
Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
- Trial name
- EMPADINE (NCT03297294)
- Testing
- EMA401
- Where
- 64 sites in Australia, Austria and 14 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Neuropathies
Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China
To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00408993
- Testing
- Duloxetine Hydrochloride
- Where
- 7 sites in China
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathy
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
The purpose of this study is to see if an investigational drug known as the lidocaine 5% patch is safe and effective in reducing the symptoms of diabetic neuropathy, to examine how topical lidocaine affects the nerve endings, and…
- Trial name
- NCT01086150
- Testing
- Skin biopsy, Lidocaine 5% patches
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Diabetic Peripheral Neuropathic Pain
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
The purpose of this study is to test the safety and efficacy of study drug LY3526318 for the treatment of diabetic peripheral neuropathic pain (DPNP).
- Trial name
- NCT05177094
- Testing
- LY3526318
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy
Study of DA-9801 to Treat Diabetic Neuropathy
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
- Trial name
- NCT01822925
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- 14 sites in United States
- Volunteers
- 128 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Diabetic Peripheral Neuropathic Pain
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.
- Trial name
- NCT02417935
- Testing
- Duloxetine, Pregabalin
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Neuropathy
Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain
This study is to see if applying red and violet low-level laser light can help to reduce foot pain associated with diabetic peripheral neuropathy,
- Trial name
- NCT05091047
- Testing
- Erchonia EVRL
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Erchonia Corporation
Peripheral Neuropathy, Neuropathic Pain
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of…
- Trial name
- NCT00603265
- Testing
- ADL5859, Duloxetine
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diabetic Peripheral Neuropathy
An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain
The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT04006392
- Testing
- Erchonia FX-635
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Erchonia Corporation
Painful Diabetic Neuropathy
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.
- Trial name
- NCT00980746
- Testing
- Eslicarbazepine acetate
- Volunteers
- 557 people
- Sponsor
- Bial - Portela C S.A.
Diabetic Peripheral Neuropathic Pain
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain.
- Trial name
- NCT05620576
- Testing
- LY3857210
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00322621
- Testing
- Duloxetine
- Where
- 19 sites in Brazil, France and 2 more
- Volunteers
- 216 people
- Sponsor
- Eli Lilly and Company